L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lytix Biopharma AS
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Total Current Liabilities
kr12.5m
CAGR 3-Years
0%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Total Current Liabilities
kr172.5m
CAGR 3-Years
8%
CAGR 5-Years
18%
CAGR 10-Years
6%
B
Bergenbio ASA
OSE:BGBIO
Total Current Liabilities
kr41.4m
CAGR 3-Years
-13%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Total Current Liabilities
kr17.7m
CAGR 3-Years
-2%
CAGR 5-Years
5%
CAGR 10-Years
7%
N
Nykode Therapeutics ASA
OSE:NYKD
Total Current Liabilities
$15.1m
CAGR 3-Years
16%
CAGR 5-Years
60%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Total Current Liabilities
kr5.2m
CAGR 3-Years
-64%
CAGR 5-Years
-45%
CAGR 10-Years
-3%
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Total Current Liabilities?
Total Current Liabilities
12.5m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Total Current Liabilities amounts to 12.5m NOK.

What is Lytix Biopharma AS's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-7%

Over the last year, the Total Current Liabilities growth was -30%.

Back to Top